1. Home
  2. CSTE vs OTLK Comparison

CSTE vs OTLK Comparison

Compare CSTE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CSTE

Caesarstone Ltd.

HOLD

Current Price

$1.47

Market Cap

27.7M

Sector

Industrials

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.26

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTE
OTLK
Founded
1987
2010
Country
Israel
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7M
29.2M
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
CSTE
OTLK
Price
$1.47
$0.26
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$2.50
AVG Volume (30 Days)
251.7K
4.4M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.91
EPS
N/A
N/A
Revenue
N/A
$8,146,123.00
Revenue This Year
$3.43
$1,430.98
Revenue Next Year
$2.83
$173.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$0.16
52 Week High
$2.79
$3.39

Technical Indicators

Market Signals
Indicator
CSTE
OTLK
Relative Strength Index (RSI) 53.07 45.14
Support Level $1.42 $0.17
Resistance Level $1.75 $0.29
Average True Range (ATR) 0.13 0.04
MACD 0.00 0.01
Stochastic Oscillator 41.87 29.02

Price Performance

Historical Comparison
CSTE
OTLK

About CSTE Caesarstone Ltd.

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: